Ribociclib, a drug developed by Swiss pharmaceutical maker Novartis, reduces breast cancer risk by a quarter in a large group of early-stage survivors, according to clinical trial results. – AFP pic, June 2, 2023.
EVEN when the disease is caught early, breast cancer recurrence is relatively commonplace – and for survivors, the prospect can be daunting. A drug developed by Swiss pharmaceutical maker Novartis reduced this risk by a quarter in a large group of early-stage survivors of the most common type of breast cancer, according to clinical trial results presented today at the American Society of Clinical Oncology’s annual meeting, offering patients new hope.
Effective July 2018, access to full reports will only be available with a subscription. Sign-up now and enjoy one week free access!